[Anti-GM1 gangliosides antibodies in multifocal motor neuropathies].
In a study on 67 chronic neuropathies, we have shown that anti-GM1 antibodies are particularly frequent in multifocal motor neuropathies (MMN) with conduction blocks (17/24 cases). The detection of these antibodies by ELISA necessitates a confirmation by immunodetection on thin-layer chromatography, so as to distinguish the anti-GM1 antibodies present in MMN from natural antibodies which are polyreactive and of low affinity. There is no direct correlation between the anti-GM1 antibody titer, the immunosuppressive treatment and the clinical evolution. Nevertheless, the detection of high titer of anti-GM1 antibodies is an additional argument in favor of treatment by IVIg.
Younes-Chennoufi
A B
AB
INSERM U 134, Hôpital de la Salpêtrière, Paris.
Baumann
N
N
D001323:Autoantibodies / Q000032:analysis / Q000502:physiology*; D002855:Chromatography, Thin Layer; D002908:Chronic Disease; D004797:Enzyme-Linked Immunosorbent Assay; D005677:G(M1) Ganglioside / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D016472:Motor Neuron Disease / Q000276:immunology* / Q000628:therapy; D010523:Peripheral Nervous System Diseases / Q000276:immunology; D013997:Time Factors
D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D005677:G(M1) Ganglioside